Abstract
NTRK gene fusions, resulting in chimeric TRK proteins, are oncogenic drivers in a diverse range of solid tumour types. Entrectinib is a potent, CNS-active TRK inhibitor approved for the treatment of adults with NTRK-fp solid tumours based on integrated analysis of three phase 1/2 trials: ALKA-372-001 (EudraCT 2012-000148-88); STARTRK-1 (NCT02097810); STARTRK-2 (NCT02568267). We present updated analyses with an additional 9 months of follow-up.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
